Evidence map›Paper›PMID 38818577›Full record

ArticleJournal of cellular and molecular medicine2024

Zhi-zi-chi decoction mitigates depression by enhancing lncRNA Six3os1 expression and promoting histone H3K4 methylation at the BDNF promoter.

Tianyu Zou, Kazuo Sugimoto, Yu Zhao, Baitao Li, Xiaomao Zhou, Cheng Peng

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Molecular medicine reports · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Frontiers in neuroscience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianyu ZouDepartment of Encephalopathy, Shenzhen Luohu District Hospital of Traditional Chinese Medicine, Shenzhen, China.ORCID 0000-0003-0431-5926
Kazuo SugimotoDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yu ZhaoDepartment of Acupuncture, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Baitao LiDepartment of Acupuncture, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Xiaomao ZhouDepartment of Encephalopathy, Shenzhen Luohu District Hospital of Traditional Chinese Medicine, Shenzhen, China.
Cheng PengDepartment of Encephalopathy, Shenzhen Luohu District Hospital of Traditional Chinese Medicine, Shenzhen, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2019A1515011789Guangdong Basic and Applied Basic Research Foundation 2021A1515110758Medical Research Projects of Guangdong Province A2024314Shenzhen Health Elite Talent Training Program 2022XKQ076Shenzhen Luohu District Soft Science LX202202041Shenzhen Luohu District Soft Science LX202302095Shenzhen Science and Technology Program JCYJ20230807150359008
6 · The paper itself

Abstract

Traditional Chinese medicine, particularly Zhi-zi-chi decoction (ZZCD), is gaining recognition as a potential treatment for depression. This study aimed to uncover the molecular mechanisms behind ZZCD's antidepressant effects, focusing on lncRNA Six3os1 and histone H3K4 methylation at the BDNF promoter. Network pharmacology and in vivo experiments were conducted to identify ZZCD targets and evaluate its impact on depression-related behaviours and neuron injury. The role of Six3os1 in recruiting KMT2A to the BDNF promoter and its effects on oxidative stress and neuron injury were investigated. ZZCD reduced depression-like behaviours and neuron injury in mice subjected to chronic stress. It upregulated Six3os1, which facilitated KMT2A recruitment to the BDNF promoter, leading to increased histone H3K4 methylation and enhanced BDNF expression. ZZCD also inhibited CORT-induced neuron injury, inflammatory response and oxidative stress in vitro. ZZCD's antidepressant properties involve Six3os1 upregulation, which exerts neuroprotective effects by inhibiting oxidative stress and neuron injury, thereby alleviating depressive symptoms. Targeting Six3os1 upregulation may offer a potential therapeutic intervention for depression.

Indexed as

Brain-Derived Neurotrophic FactorDepressionDrugs, Chinese HerbalHistonesPromoter Regions, GeneticRNA, Long NoncodingAnimalsAntidepressive AgentsDisease Models, AnimalGene Expression RegulationMaleMethylationMiceMice, Inbred C57BLNeuronsOxidative StressAntidepressive AgentsBdnf protein, mouseBrain-Derived Neurotrophic FactorDrugs, Chinese HerbalHistonesRNA, Long Noncodinganti‐depressive mechanismBDNFhistone methylationKMT2ALncRNA Six3os1neuron injurytraditional Chinese medicineZhi‐zi‐chi decoction

Identifiers

PMID38818577
PMCPMC11140235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.